Delivery Order SPE2DB20D3104-SPE2DB25FW0F3
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,869.59 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 25 mg, a pharmaceutical product used in the treatment of overactive bladder. The contract was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and represents a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) valued at $4,037.23. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The contract is scheduled for completion by August 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for pharmaceutical supply of Myrbetriq ER 50 mg tablets (30-count units) with a ceiling value of $2,383.25. This is a firm fixed-price delivery order with no set-aside designation, executed under competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This...
- The Defense Logistics Agency awarded a delivery order valued at $11,783.17 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $2,257.06 to AmerisourceBergen Drug Corp for 90 tablets of Myrbetriq ER 50 mg, a pharmaceutical product used primarily for treating overactive bladder. The contract was competitively awarded without a set-aside designation under a firm fixed-price arrangement, with the ultimate completion date set for June 18, 2025. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania served as the place of performance. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Myrbetriq ER 50 mg tablets (30-count units) with a ceiling value of $5,007.25. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. This delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $9,692.22 for Myrbetriq ER 50 mg tablets (90-count supply) on September 11, 2025, with an ultimate completion date of September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) under a firm fixed-price contract valued at $8,276.16. The award was made on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Myrbetriq ER 25 mg tablets (30-count units) valued at $1,549.42. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,290.75 on September 10, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count). This is a firm fixed price, non-set-aside contract with a completion date of September 11, 2025, and performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB20D3104Indefinite Delivery Contract
- SPE2DB20D3104-SPE2DB25FW0F3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies on September 16, 2025, with an ultimate completion date of September 17, 2025. The order, valued at $8,494.44 under a firm fixed-price contract type, covers 90 tablets of Myrbetriq ER 50 mg, a medication used to treat overactive bladder. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen serves multiple federal customers including the Defense Health Agency and U.S. Coast Guard through this comprehensive global pharmaceutical support vehicle. The company's extensive federal portfolio demonstrates its capability to fulfill diverse medical supply requirements across therapeutic domains for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 9/16/25 |